InvestorNewsBreaks – Processa Pharmaceuticals Inc. (NASDAQ: PCSA) to Present at H.C. Wainwright BIOCONNECT 2021
January 11, 2021
Processa Pharmaceuticals (NASDAQ: PCSA), a clinical-stage biopharmaceutical company developing products to improve the survival and/or quality of life for patients who have unmet medical needs, today announced that management will present at the H.C. Wainwright BIOCONNECT 2021 Virtual Conference. According to the update, the presentation is now available for on-demand listening by visiting https://ibn.fm/OVOdD. In […]
InvestorNewsBreaks – Processa Pharmaceuticals Inc. (NASDAQ: PCSA) Featured in Research Report
December 10, 2020
Processa Pharmaceuticals (NASDAQ: PCSA), a clinical-stage biopharmaceutical company developing products to improve the survival and/or quality of life for patients who have unmet medical needs, was featured in a research report by the Benchmark Company LLC. The report, titled “Processa Pharmaceuticals Inc. (PCSA) Processing Assets to the FDA; Initiate at Buy,” lists a $15 price […]
InvestorNewsBreaks – Processa Pharmaceuticals Inc. (NASDAQ: PCSA) Featured in Korea Biomedical Review Article
November 24, 2020
Processa Pharmaceuticals (NASDAQ: PCSA), a clinical-stage biopharmaceutical company developing products to improve the survival and/or quality of life for patients who have unmet medical needs, was featured in a recent article published in the Korea Biomedical Review. The piece, titled “Yuhan emerges as global new-drug developer with $3.6 billion tech export,” discusses Yuhan Corp.’s (OCT: […]
InvestorNewsBreaks – Processa Pharmaceuticals Inc. (NASDAQ: PCSA) Announces Participation Schedule for Upcoming Investor Conferences
November 16, 2020
Processa Pharmaceuticals (NASDAQ: PCSA), a clinical-stage biopharmaceutical company developing products to improve the survival and/or quality of life for patients who have unmet medical needs, today announced that management will participate in two upcoming investor conferences. According to the update, Processa will participate in one-on-one meetings at the Craig-Hallum Alpha Select Virtual Conference on Tuesday, […]
Processa Pharmaceuticals to Participate in Upcoming Investor Conferences
November 16, 2020
Processa’s pipeline includes several clinical-stage drug candidates HANOVER, MD., Nov. 16, 2020 (GLOBE NEWSWIRE) — via InvestorWire – Processa Pharmaceuticals, Inc. (NASDAQ: PCSA), (“Processa” or the “Company”), a clinical-stage biopharmaceutical company developing products to improve the survival and/or quality of life for patients who have unmet medical needs, announced today that management will participate in […]
InvestorNewsBreaks – Processa Pharmaceuticals Inc. (NASDAQ: PCSA) Announces Q3 2020 Results, Provides Corporate Update
November 13, 2020
Processa Pharmaceuticals (NASDAQ: PCSA), a clinical-stage biopharmaceutical company focused on the development of drug products intended to provide treatment for and improve the survival and/or quality of life for patients with unmet medical needs or no alternative treatment, on Thursday released its financial results for the third quarter of 2020. In addition, Processa provided a […]
Processa Pharmaceuticals Announces Third Quarter 2020 Results, Provides Corporate Update
November 12, 2020
Highlights include closing $19.2 million public offering, uplisting to Nasdaq, and positive progress with multiple candidates currently in Processa’s clinical drug pipeline HANOVER, MD., Nov. 12, 2020 (GLOBE NEWSWIRE) — via InvestorWire — Processa Pharmaceuticals, Inc. (NASDAQ: PCSA) (“Processa” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of drug products that are intended to […]
InvestorNewsBreaks – Processa Pharmaceuticals Inc. (NASDAQ: PCSA) Announces Board Appointment of Dr. Khalid Islam
November 5, 2020
Processa Pharmaceuticals (NASDAQ: PCSA), a clinical-stage biopharmaceutical company developing products to improve survival and/or quality of life for patients with a high unmet medical need, today announced the appointment of Dr. Khalid Islam to its board of directors. Dr. Islam was the chairman and CEO of Gentium S.p.A. (a Nasdaq-listed company; 2009-2014) where he led […]
InvestorNewsBreaks – Processa Pharmaceuticals Inc. (NASDAQ: PCSA) Featured in Research Report
November 4, 2020
Processa Pharmaceuticals (NASDAQ: PCSA), a clinical-stage biopharmaceutical company developing products to improve survival and/or quality of life for patients with high unmet medical need conditions, was featured in an institutional research report by Craig-Hallum Capital Group LLC. The report discusses Craig-Hallum’s research coverage of PCSA and details the company’s experienced management team and its ownership […]
InvestorNewsBreaks – Processa Pharmaceuticals Inc. (NASDAQ: PCSA) to Host Call, Live Webcast to Discuss Q3 2020 Results, Clinical Pipeline
November 3, 2020
Processa Pharmaceuticals (NASDAQ: PCSA), a clinical-stage biopharmaceutical company developing products to improve survival and/or quality of life for patients with high unmet medical need conditions, today announced that it will host a conference call and live webcast at 5:30 p.m. Eastern Time on Nov. 12, 2020. Topics will include review of the company’s third quarter […]
Processa Pharmaceuticals Schedules Conference Call to Discuss Third Quarter Results and Provide Drug Development Update on Nov. 12 at 5:30 p.m. ET
November 3, 2020
HANOVER, Md., Nov. 03, 2020 (GLOBE NEWSWIRE) — via InvestorWire — Processa Pharmaceuticals, Inc. (NASDAQ: PCSA) (“Processa” or the “Company”), a clinical-stage biopharmaceutical company developing products to improve survival and/or quality of life for patients who have high unmet medical need conditions, today announces it will host a conference call and live webcast on Nov. […]
InvestorNewsBreaks – Why Processa Pharmaceuticals Inc. (NASDAQ: PCSA) Is ‘One to Watch’
November 2, 2020
Processa Pharmaceuticals (NASDAQ: PCSA) is a clinical-stage biopharmaceutical company focused on the development of drug products for patients with high unmet medical need conditions or no alternative treatment options. A recent article discussing the company reads, “Headquartered in Hanover, Maryland, Processa has built a pipeline of drugs, which already have proof-of-concept data supporting clinical use […]